Skip to main content

Table 1 Distribution of patients by baseline clinical variables.

From: Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

Variable

Category

Number (%)

  

N = 664

Sex

Female

311 (46.8)

 

Male

353 (53.2)

Age

Less than 75 years

496 (74.7)

 

75 years or older

168 (25.3)

Chemotherapy

CHOP

334 (50.3)

 

PMitCEBO

330 (49.7)

GCSF

No

330 (49.7)

 

Yes

334 (50.3)

Stage

I

70 (10.5)

 

II

176 (26.5)

 

III

193 (29.1)

 

IV

225 (33.9)

B symptoms

No

311 (46.8)

 

Yes

353 (53.2)

ECOG Performance status

0

206 (31.0)

 

1

264 (39.8)

 

2

131 (19.7)

 

3

39 (5.9)

 

4

13 (2.0)

 

No data

11 (1.7)

Plasma LDH concentration (mU/L)

  
 

Normal (0.2–0.5)

216 (32.5)

 

Elevated (> 0.5)

381 (57.4)

 

No data

67 (10.1)

Bone marrow aspirate

Not involved

508 (76.5)

 

Involved

57 (8.6)

 

No data

99 (14.9)

Bone marrow trephine

Not involved

487 (73.3)

 

Involved

89 (13.4)

 

No data

88 (13.3)